JP2017500584A5 - - Google Patents

Download PDF

Info

Publication number
JP2017500584A5
JP2017500584A5 JP2016549205A JP2016549205A JP2017500584A5 JP 2017500584 A5 JP2017500584 A5 JP 2017500584A5 JP 2016549205 A JP2016549205 A JP 2016549205A JP 2016549205 A JP2016549205 A JP 2016549205A JP 2017500584 A5 JP2017500584 A5 JP 2017500584A5
Authority
JP
Japan
Prior art keywords
assay
biological sample
hmwk
autoimmune disease
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016549205A
Other languages
English (en)
Japanese (ja)
Other versions
JP6657098B2 (ja
JP2017500584A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/061242 external-priority patent/WO2015061182A1/en
Publication of JP2017500584A publication Critical patent/JP2017500584A/ja
Publication of JP2017500584A5 publication Critical patent/JP2017500584A5/ja
Application granted granted Critical
Publication of JP6657098B2 publication Critical patent/JP6657098B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016549205A 2013-10-21 2014-10-17 自己免疫疾患の診断と治療 Active JP6657098B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361893542P 2013-10-21 2013-10-21
US61/893,542 2013-10-21
PCT/US2014/061242 WO2015061182A1 (en) 2013-10-21 2014-10-17 Diagnosis and treatment of autoimmune diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020018129A Division JP7157089B2 (ja) 2013-10-21 2020-02-05 自己免疫疾患の診断と治療

Publications (3)

Publication Number Publication Date
JP2017500584A JP2017500584A (ja) 2017-01-05
JP2017500584A5 true JP2017500584A5 (enExample) 2017-11-30
JP6657098B2 JP6657098B2 (ja) 2020-03-04

Family

ID=52993412

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016549205A Active JP6657098B2 (ja) 2013-10-21 2014-10-17 自己免疫疾患の診断と治療
JP2020018129A Active JP7157089B2 (ja) 2013-10-21 2020-02-05 自己免疫疾患の診断と治療
JP2022161469A Active JP7541560B2 (ja) 2013-10-21 2022-10-06 自己免疫疾患の診断と治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020018129A Active JP7157089B2 (ja) 2013-10-21 2020-02-05 自己免疫疾患の診断と治療
JP2022161469A Active JP7541560B2 (ja) 2013-10-21 2022-10-06 自己免疫疾患の診断と治療

Country Status (14)

Country Link
US (3) US10101344B2 (enExample)
EP (2) EP3060908B1 (enExample)
JP (3) JP6657098B2 (enExample)
KR (3) KR102295623B1 (enExample)
CN (2) CN110658337B (enExample)
AU (4) AU2014340449B2 (enExample)
BR (1) BR112016008975B1 (enExample)
CA (1) CA2927695C (enExample)
DK (1) DK3060908T3 (enExample)
ES (1) ES2873204T3 (enExample)
IL (4) IL284969B (enExample)
PL (1) PL3060908T3 (enExample)
PT (1) PT3060908T (enExample)
WO (1) WO2015061182A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL273688B2 (en) 2013-01-20 2024-12-01 Dyax Corp Evaluation and treatment of bradykinin-mediated disorders
WO2015061182A1 (en) * 2013-10-21 2015-04-30 Dyax Corp. Diagnosis and treatment of autoimmune diseases
EP3060582B1 (en) 2013-10-21 2020-09-23 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
EP3839514B1 (en) 2015-10-19 2023-12-13 Takeda Pharmaceutical Company Limited Immunoassay to detect cleaved high molecular weight kininogen
KR20250073510A (ko) 2016-09-16 2025-05-27 다케다 파머수티컬 컴패니 리미티드 접촉 활성화 시스템과 연관된 질환을 위한 단백질 바이오마커
KR200490846Y1 (ko) 2019-04-09 2020-01-13 이대호 각도조절 브라켓
EP4126219A2 (en) * 2020-04-04 2023-02-08 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome
KR20230050770A (ko) 2021-10-08 2023-04-17 김경민 발로 열 수 있는 반려동물 울타리
EP4548103A2 (en) * 2022-06-30 2025-05-07 Takeda Pharmaceutical Company Limited Protein biomarkers for lanadelumab treatment

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
CA1312564C (en) 1985-07-12 1993-01-12 Robert W. Colman Monoclonal antibodies to human plasma prekallikrein and methods of preparing and using same
US5047323A (en) 1986-01-22 1991-09-10 Temple University Of The Commonwealth System Of Higher Education Method for detecting human kininogen using monoclonal antibodies thereto
US4908431A (en) 1986-01-22 1990-03-13 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human kininogen and methods of preparing same
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPS63185398A (ja) 1986-09-10 1988-07-30 Nippon Zoki Pharmaceut Co Ltd 生理活性物質測定法
US4882272A (en) 1986-10-01 1989-11-21 Temple University - Of The Commonwealth System Of Higher Education High molecular weight kininogen assay
US5025796A (en) * 1988-12-01 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Apparatus and methods for determining in vivo response to thermal stimulation in in an unrestrained subject
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5472945A (en) 1991-08-13 1995-12-05 Temple University- Of The Commonwealth System Of Higher Education Modulation of blood pressure and inhibition of platelet activation with kininogen fragment
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
PT739355E (pt) 1994-01-11 2005-01-31 Dyax Corp Proteinas de 'dominio de kunitz' inibidoras de calicreina e seus analogos
AU7398996A (en) 1995-10-11 1997-04-30 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and method
JPH1084995A (ja) 1996-09-12 1998-04-07 Nippon Zoki Pharmaceut Co Ltd 血液凝固第ｘｉｉ因子活性化法
US5789261A (en) 1996-10-30 1998-08-04 Temple University Of The Commonwealth System Of Higher Education Solid phase immunoassay
US6242210B1 (en) 1997-05-20 2001-06-05 Actinova Limited Treatment of bacterial infections
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
JP4346798B2 (ja) 1999-08-19 2009-10-21 協和メデックス株式会社 Ｈｃｖコア抗原の検出または定量方法およびそれに用いる検出または定量試薬。
US6994852B1 (en) 1999-11-12 2006-02-07 Temple University-Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
US7678541B2 (en) 2000-11-21 2010-03-16 Hologic, Inc. Methods and compositions for the detection of a nucleic acid using a non-invasive cleavage reaction
JP2002221519A (ja) 2001-01-29 2002-08-09 Sysmex Corp 抗凝固剤およびそれを用いた抗凝固剤処理方法
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
CA2447851C (en) 2001-06-28 2012-08-28 Domantis Limited Dual-specific ligand and its use
US6913900B2 (en) 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
JP4106888B2 (ja) 2001-09-19 2008-06-25 カシオ計算機株式会社 液晶表示装置および携帯端末装置
US8148171B2 (en) 2001-10-09 2012-04-03 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and methods
CA2488558C (en) 2002-06-07 2013-08-20 Dyax Corp. Prevention and reduction of blood loss
US7435542B2 (en) 2002-06-24 2008-10-14 Cornell Research Foundation, Inc. Exhaustive selection of RNA aptamers against complex targets
US20070003552A1 (en) 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
US20050053954A1 (en) 2002-11-01 2005-03-10 Brennan John D. Multicomponent protein microarrays
WO2005024042A2 (en) 2003-09-04 2005-03-17 The Regents Of The University Of California Aptamers and methods for their in vitro selection and uses thereof
JP5543052B2 (ja) 2003-11-22 2014-07-09 株式会社テクノメディカ アプタマーを用いた標的分子の検出方法
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
AU2005271523B2 (en) 2004-08-03 2011-09-15 Dyax Corp. hk1-binding proteins
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
AU2005293752A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease
RU2464276C2 (ru) 2005-05-18 2012-10-20 Аблинкс Н.В. Улучшенные нанотела против фактора некроза опухоли-альфа
PT1981519T (pt) 2005-12-29 2018-02-23 Dyax Corp Inibição de protéases
AU2007281220B2 (en) 2006-07-31 2013-08-15 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
WO2008064336A2 (en) * 2006-11-22 2008-05-29 Inivitrogen Corporation Autoimmune disease biomarkers
WO2008100791A1 (en) 2007-02-16 2008-08-21 Rules-Based Medicine, Inc. Methods and kits for the diagnosis of sickle cell
EP2195010A4 (en) * 2007-08-21 2012-03-14 Genzyme Corp TREATMENT WITH INHIBITORS OF KALLIKREINE
CA2703264A1 (en) 2007-10-22 2009-04-30 Georg Dewald Disorders of vasoregulation and methods of diagnosing them
AU2009269257A1 (en) * 2008-07-07 2010-01-14 Nippon Zoki Pharmaceutical Co., Ltd. Method for detection of fibromyalgia
JP2012507723A (ja) 2008-11-03 2012-03-29 シェーリング コーポレイション 炎症性腸疾患生物マーカーおよび関連治療方法
EP2369930A4 (en) 2008-12-02 2012-10-03 Joslin Diabetes Ct METHOD OF REDUCING BLOOD PRESSURE USING PLASMATIC KALLICREIN INHIBITORS
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
FR2942233B1 (fr) 2009-02-19 2015-03-13 Lfb Biotechnologies Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre
KR101077275B1 (ko) * 2009-05-07 2011-10-27 한국기초과학지원연구원 당단백질의 당쇄화를 이용한 암 진단 방법
JP5299179B2 (ja) * 2009-09-02 2013-09-25 株式会社リコー 画像形成装置
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
US9206123B2 (en) * 2009-12-18 2015-12-08 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
JP2013515000A (ja) 2009-12-18 2013-05-02 アクティベサイト ファーマシューティカルズ インコーポレイティッド 血漿カリクレインの阻害薬のプロドラッグ
RS62853B1 (sr) 2010-01-06 2022-02-28 Takeda Pharmaceuticals Co Proteini koji vezuju kalikrein plazme
WO2012009447A2 (en) * 2010-07-13 2012-01-19 University Of Rochester THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF
US10299714B2 (en) 2010-12-02 2019-05-28 Becton, Dickinson And Company Blood collection devices containing blood stabilization agent including variegin or analog thereof and/or a polysulfated disaccharide
AU2012204202A1 (en) 2011-01-06 2013-07-11 Dyax Corp. Plasma kallikrein binding proteins
CA2838984A1 (en) 2011-06-10 2012-12-13 Isis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
US9187749B2 (en) * 2011-06-10 2015-11-17 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
IL273688B2 (en) 2013-01-20 2024-12-01 Dyax Corp Evaluation and treatment of bradykinin-mediated disorders
EP2950718A4 (en) 2013-02-01 2016-09-21 Becton Dickinson Co BLUTSAMMELVORRICHTUNGEN WITH CONTACT PATH -HEMMENDEN ADDITIVES
WO2015061182A1 (en) 2013-10-21 2015-04-30 Dyax Corp. Diagnosis and treatment of autoimmune diseases
EP3060582B1 (en) 2013-10-21 2020-09-23 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
PT3096798T (pt) 2014-01-21 2021-02-25 Dyax Corp Proteínas de ligação à calicreína plasmática e seus usos no tratamento de angioedema hereditário
EP3839514B1 (en) 2015-10-19 2023-12-13 Takeda Pharmaceutical Company Limited Immunoassay to detect cleaved high molecular weight kininogen
AU2016372159B2 (en) 2015-12-15 2022-03-24 Takeda Pharmaceutical Company Limited Peptide quantitation assay for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK
US20230072523A1 (en) * 2020-01-28 2023-03-09 Orgenesis Inc. Process and system for acellular therapy

Similar Documents

Publication Publication Date Title
JP2017500584A5 (enExample)
JP2016536012A5 (enExample)
Louis et al. Extra-pulmonary complications in SARS-CoV-2 infection: a comprehensive multi organ-system review
JP2017524130A5 (enExample)
Erickson et al. Serum amyloid A: an ozone-induced circulating factor with potentially important functions in the lung-brain axis
Hisada et al. Circulating tissue factor‐positive extracellular vesicles and their association with thrombosis in different diseases
CY1121872T1 (el) Αξιολογηση, δοκιμασιες και θεραπεια των pkal-μεσολαβουμενων διαταραχων
Tomerak et al. Systemic inflammation in COVID‐19 patients may induce various types of venous and arterial thrombosis: a systematic review
Boccatonda et al. Long-term hypercoagulability, endotheliopathy and inflammation following acute SARS-CoV-2 infection
JP2010516678A5 (enExample)
WO2012017466A8 (en) Use of hmgb1 as a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof
Jia et al. Rho kinase mediates Porphyromonas gingivalis outer membrane vesicle-induced suppression of endothelial nitric oxide synthase through ERK1/2 and p38 MAPK
WO2013009703A3 (en) Antibodies, kit and method for detecting amyloid beta oligomers
JP2017505897A5 (enExample)
JP2020091296A5 (enExample)
Beltrán-Camacho et al. The serum of COVID-19 asymptomatic patients up-regulates proteins related to endothelial dysfunction and viral response in circulating angiogenic cells ex-vivo
EA201490105A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
BR112017004883A2 (pt) ensaio de diagnóstico baseado em fragmento de rgma
EA201491411A1 (ru) Растворимый manf при поражениях бета-клеток поджелудочной железы
JP2006311860A5 (enExample)
JP2016519761A5 (enExample)
Rottenstreich et al. Assessment of the procoagulant potential after laparoscopic sleeve gastrectomy: a potential role for extended thromboprophylaxis
Zhang et al. Proteomic analysis associated with coronary artery dilatation caused by Kawasaki disease using serum exosomes
Brochado et al. HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients
Huckriede et al. Markers of NETosis and DAMPs are altered in critically ill COVID-19 patients